Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study

Journal of Surgical Oncology

Volumn 98, Issue 1, 2008, Pages 34-41

  Hsu, Feng Ming ^a   Lin, Chia Chi ^a,b   Lee, Jang Ming ^a   Chang, Yih Leong ^a   Hsu, Chih Hung ^a,b   Tsai, Yu Chieh ^a,b   Lee, Yung Chie ^a   Cheng, Jason Chia Hsien ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Chemoradiation; Esophageal cancer; Paclitaxel; Squamous cell carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; LOW DRUG DOSE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; SURVIVAL TIME; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PREMEDICATION; PROGNOSIS; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 47149097863     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21063     Document Type: Article

References (40)

1. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003;349:2241-2252.
2. Allen JW, Richardson JD, Edwards MJ: Squamous cell carcinoma of the esophagus: A review and update. Surg Oncol 1997;6:193-200.
3. Ohtsu A: Chemoradiotherapy for esophageal cancer: Current status and perspectives. Int J Clin Oncol 2004;9:444-450.
4. Nygaard K, Hagen S, Hansen HS, et al.: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104-1109.
5. Apinop C, Puttisak P, Preecha N: A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994;41:391-393.
6. Bosset JF, Gignoux M, Triboulet JP, et al.: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-167.
7. Urba SG, Orringer MB, Turrisi A, et al.: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313.
8. Burmeister BH, Smithers BM, Gebski V, et al.: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 2005;6:659-668.
9. Urschel JD, Vasan H: A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-543.
10. Fiorica F, Di Bona D, Schepis F, et al.: Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut 2004;53:440-441.
11. Malthaner RA, Wong RK, Rumble RB, et al.: Neoadjuvant or adjuvant therapy for resectable esophageal cancer: A systematic review and meta-analysis. BMC Med 2004;2:35.
12. Gebski V, Burmeister B, Simithers BM, et al.: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007;8:226-234.
13. Cooper JS, Guo MD, Herskovic A, et al.: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627.
14. Le Prise E, Etienne PL, Meunier B, et al.: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1779-1784.
15. Lee JL, Park SI, Kim SB, et al.: A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004;15:947-954.
16. Hsu CH, Yeh KH, Lui LT, et al.: Concurrent chemoradiotherapy for locally advanced esophageal cancer - A pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil. Anticancer Res 1999;19:4463-4467.
17. Bedenne L, Michel P, Bouche O, et al.: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-1168.
18. Kleinberg L, Knisely JP, Heitmiller R, et al.: Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003;56:328-334.
19. Chiu PW, Chan AC, Leung SF, et al.: Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: Early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005;9:794-802.
20. Ajani JA, Ilson DH, Daugherty K, et al.: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086-1091.
21. van Meerten E, Muller K, Tilanus HW, et al.: Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: A phase II study. Br J Cancer 2006;94:1389-1394.
22. Henry LR, Goldberg M, Scott W, et al.: Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: A phase II report. Ann Surg Oncol 2006;13:214-220.
23. Lin CC, Hsu CH, Chen JC, et al.: Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007;18:93-98.
24. Adelstein DJ, Rice TW, Rybicki LA, et al.: Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000;18:2032-2039.
25. Roof KS, Coen J, Lynch TJ, et al.: Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2006;65:1120-1128.
26. Wu X, Chen VW, Ruiz B, et al.: Incidence of esophageal and gastric carcinomas among American Asians/Pacific Islanders, whites, and blacks: Subsite and histology differences. Cancer 2006;106:683-692.
27. Rohatgi PR, Swisher SG, Correa AM, et al.: Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 2006;106:552-558.
28. Malthaner RA, Wong RK, Rumble RB, et al.: Neoadjuvant or adjuvant therapy for resectable esophageal cancer: A clinical practice guideline. BMC Cancer 2004;4:67.
29. Stahl M, Stuschke M, Lehmann N, et al.: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-2317.
30. Abou-Jawde RM, Mekhail T, Adelstein DJ, et al.: Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer. Chest 2005;128:250-255.
31. Doty JR, Salazar JD, Forastiere AA, et al.: Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy. Ann Thorac Surg 2002;74:227-231.
32. Wouters MW, Wijnhoven BP, Karim-Kos HE, et al.: High-Volume versus Low-Volume for Esophageal Resections for Cancer: The Essential Role of Case-Mix Adjustments based on Clinical Data. Ann Surg Oncol 2008;15:80-87.
33. Seung SK, Smith JW, Molendyk J, et al.: Selective dose escalation of chemoradiotherapy for esophageal cancer: Role of treatment intensification. Semin Oncol 2004;31:13-19.
34. Vermorken JB, Remenar E, van Herpen C, et al.: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1654-1704.
35. Posner MR, Hershock DM, Blajman CR, et al.: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715.
36. Heath EI, Burtness BA, Heitmiller RF, et al.: Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000;18:868-876.
37. Lee J, Lee KE, Im YH, et al.: Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Ann Thorac Surg 2005;80:1170-1175.
38. Ando N, Iizuka T, Ide H, et al.: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study - JC OG9204. J Clin Oncol 2003;21:4592-4596.
39. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.
40. Nakajima T, Kinoshita T, Nashimoto A, et al.: Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007;94:1468-1476.